XML 21 R12.htm IDEA: XBRL DOCUMENT
v3.22.0.1

STOCK PLANS AND STOCK-BASED COMPENSATION | 9 Months Ended
--- | ---
Dec. 31, 2021
STOCK PLANS AND STOCK-BASED COMPENSATION |
STOCK PLANS AND STOCK-BASED COMPENSATION | 3. STOCK PLANS AND STOCK-BASED COMPENSATION Stock Option Plans - In July 2003, shareholders of the Company approved the adoption of the 2003 Stock Option Plan (“2003 Plan”). The 2003 Plan was effective in July 2003 and expired in July 2013. Accordingly, no further option awards may be granted under the 2003 Plan; however, any awards granted prior to their respective expiration dates remain outstanding subject to their terms. Each option granted under the 2003 Plan has an exercise price equal to the fair market value of the Company’s common stock on the date of the grant, a maximum term of ten years and a vesting period from zero to five years. ​ In July 2017, the shareholders of the Company approved the Riverview Bancorp, Inc. 2017 Equity Incentive Plan (“2017 Plan”). The 2017 Plan provides for the grant of incentive stock options, non-qualified stock options, restricted stock and restricted stock units. The Company has reserved 1,800,000 shares of its common stock for issuance under the 2017 Plan. The 2003 Plan and the 2017 Plan are collectively referred to as “the Stock Option Plans”. ​ The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes stock option valuation model. The fair value of all awards is amortized on a straight-line basis over the requisite service periods, which are generally the vesting periods. The expected life of options granted represents the period of time that they are expected to be outstanding. The expected life is determined based on historical experience with similar options, giving consideration to the contractual terms and vesting schedules. Expected volatility is estimated at the date of grant based on the historical volatility of the Company's common stock. Expected dividends are based on dividend trends and the market value of the Company's common stock at the time of grant. The risk-free interest rate for periods within the contractual life of the options is based on the U.S. Treasury yield curve in effect at the time of the grant. There were no stock options granted under the 2017 Stock Option Plan during the nine months ended December 31, 2021 and 2020. ​ As of December 31, 2021, all outstanding stock options were fully vested and there was no remaining unrecognized compensation expense related to stock options granted under the Stock Option Plans. There was no stock-based compensation expense related to stock options for the nine months ended December 31, 2021 and 2020 under the Stock Option Plans. ​ The following table presents the activity related to stock options under the Stock Option Plans for the periods shown: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended December 31, | ​ | Nine Months Ended December 31, | ​
​ |  | 2021 | ​ | 2020 |
​ |  | ​ |  | Weighted |  | ​ |  | Weighted |
​ | ​ | ​ | ​ | Average | ​ | ​ | ​ | Average | ​
​ | ​ | Number of | ​ | Exercise | ​ | Number of | ​ | Exercise | ​
​ |  | Shares |  | Price |  | Shares |  | Price |
Balance, beginning of period |  | 23,332 | ​ | $ | 2.78 |  | 43,332 | ​ | $ | 2.69 |
Options exercised |  | (6,000) | ​ |  | 2.78 |  | (14,000) | ​ |  | 2.49 |
Balance, end of period |  | 17,332 | ​ | $ | 2.78 |  | 29,332 | ​ | $ | 2.78 |
​ The following table presents information on stock options outstanding, less estimated forfeitures, as of December 31, 2021 and 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2021 | ​ | 2020 | ​
Stock options fully vested and expected to vest: |  | ​ |  |  | ​ |  | ​
Number |  | ​ | 17,332 |  | ​ | 29,332 | ​
Weighted average exercise price | ​ | $ | 2.78 | ​ | $ | 2.78 | ​
Aggregate intrinsic value (1) | ​ | $ | 85,000 | ​ | $ | 73,000 | ​
Weighted average contractual term of options (years) | ​ |  | 1.54 | ​ |  | 2.54 | ​
Stock options fully vested and currently exercisable: | ​ |  | ​ | ​ |  | ​ | ​
Number | ​ |  | 17,332 | ​ |  | 29,332 | ​
Weighted average exercise price | ​ | $ | 2.78 | ​ | $ | 2.78 | ​
Aggregate intrinsic value (1) | ​ | $ | 85,000 | ​ | $ | 73,000 | ​
Weighted average contractual term of options (years) | ​ |  | 1.54 | ​ |  | 2.54 | ​
(1) | The aggregate intrinsic value of a stock option in the table above represents the total pre-tax intrinsic value (the amount by which the current market value of the underlying stock exceeds the exercise price) that would have been received by the option holders had all option holders exercised. This amount changes based on changes in the market value of the Company’s stock.
The total intrinsic value of stock options exercised was $25,000 and $41,000 for the nine months ended December 31, 2021 and 2020, respectively, under the Stock Option Plans. ​ The Company may grant restricted stock pursuant to the 2017 Plan of which vesting can either be time based or performance based. Performance based awards are subject to attaining certain performance metrics and all, or a portion of, the performance based awards can subsequently be cancelled for not attaining the predetermined performance metrics. The fair value of restricted stock awards is equal to the fair value of the Company’s stock on the date of grant. The related stock-based compensation expense is recorded over the requisite service period. Stock-based compensation related to restricted stock grants was $112,000 and $84,000 for the three months ended December 31, 2021 and 2020, respectively. Stock-based compensation related to restricted stock grants was $289,000 and $268,000 for the nine months ended December 31, 2021 and 2020, respectively. The unrecognized stock-based compensation related to restricted stock was $549,000 and $432,000 at December 31, 2021 and 2020, respectively. The weighted average vesting period for the restricted stock was 1.78 years and 1.87 years at December 31, 2021 and 2020, respectively. ​ The following tables presents the activity related to restricted stock for the nine months ended December 31, 2021 and 2020: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Time Based |  | Performance Based |  | Total
​ | ​ | Number | ​ | Weighted | ​ | Number | ​ | Weighted | ​ | Number | ​ | Weighted
​ | ​ | of | ​ | Average | ​ | of | ​ | Average | ​ | of | ​ | Average
​ | ​ | Unvested | ​ | Market | ​ | Unvested | ​ | Market | ​ | Unvested | ​ | Market
Nine Months Ended December 31, 2021 |  | Shares |  | Price |  | Shares |  | Price |  | Shares |  | Price
Balance, beginning of period |  | 45,616 | ​ | $ | 6.57 |  | 96,772 | ​ | $ | 5.27 |  | 142,388 | ​ | $ | 5.69
Granted |  | 15,274 | ​ |  | 7.08 |  | 54,011 | ​ |  | 7.06 |  | 69,285 | ​ |  | 7.06
Forfeited |  | — | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | —
Vested |  | (29,618) | ​ |  | 7.43 |  | (12,732) | ​ |  | 8.35 |  | (42,350) | ​ |  | 7.71
Cancelled |  | — | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | —
Balance, end of period |  | 31,272 | ​ | $ | 6.00 |  | 138,051 | ​ | $ | 5.69 |  | 169,323 | ​ | $ | 5.75
​ ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Time Based |  | Performance Based |  | Total
​ | ​ | Number | ​ | Weighted | ​ | Number | ​ | Weighted | ​ | Number | ​ | Weighted
​ | ​ | of | ​ | Average | ​ | of | ​ | Average | ​ | of | ​ | Average
​ | ​ | Unvested | ​ | Market | ​ | Unvested | ​ | Market | ​ | Unvested | ​ | Market
Nine Months Ended December 31, 2020 |  | Shares |  | Price |  | Shares |  | Price |  | Shares |  | Price
Balance, beginning of period |  | 49,298 | ​ | $ | 8.35 |  | 33,375 | ​ | $ | 8.35 |  | 82,673 | ​ | $ | 8.35
Granted |  | 19,453 | ​ |  | 4.17 |  | 71,310 | ​ |  | 4.17 |  | 90,763 | ​ |  | 4.17
Forfeited |  | — | ​ |  | — |  | — | ​ |  | — |  | — | ​ |  | —
Vested |  | (23,135) | ​ |  | 8.35 |  | — | ​ |  | — |  | (23,135) | ​ |  | 8.35
Cancelled |  | — | ​ |  | — |  | (7,913) | ​ |  | 8.35 |  | (7,913) | ​ |  | 8.35
Balance, end of period |  | 45,616 | ​ | $ | 6.57 |  | 96,772 | ​ | $ | 5.27 |  | 142,388 | ​ | $ | 5.69
​ ​ ​ Trust Company Stock Options – At December 31, 2021, there were no Trust Company stock options outstanding. At December 31, 2020, there were 500 Trust Company stock options outstanding, which had been granted to the President and Chief Executive Officer of the Trust Company. During the three and nine months ended December 31, 2021, there was no stock-based compensation expense related to these options. During the three and nine months ended December 31, 2020, the Trust Company incurred $11,000 and $33,000 of stock-based compensation expense related to these options, respectively. During the nine months ended December 31, 2021 and 2020, 500 Trust Company stock options were exercised. There were no Trust Company stock options granted during the nine months ended December 31, 2021 and 2020. There was no unrecognized compensation expense and $11,000 related to the Trust Company stock options as of December 31, 2021 and 2020, respectively.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration